| Literature DB >> 18690106 |
Rebecca E Nordquist1, Helene Savignac, Meike Pauly-Evers, Gaby Walker, Fred Knoflach, Edilio Borroni, Patricia Glaentzlin, Bernd Bohrmann, Jurg Messer, Laurence Ozmen, Anita Albientz, Will Spooren.
Abstract
The neurokinin 3 (NK3) receptor is a novel target under investigation for improvement of symptoms of schizophrenia, because of its ability to modulate dopaminergic signaling. To further understanding of the function of this receptor, sensitivity to dopaminergic stimuli and levels of dopaminergic receptors and tyrosine hydroxylase in NK3 receptor knockout mice were studied. Knockout of the receptor was confirmed by lack of NK3 protein and lack of electrophysiological responsivity of presumed dopaminergic neurons to senktide. NK3 receptor knockout mice showed mild hyperlocomotion and deficits on the rotarod. NK3 receptor knockout mice did not show significant differences in sensitivity to locomotor effects of acute amphetamine (0.3, 1, and 3 mg/kg subcutaneously) or significant alterations in sensitization to locomotor effects of amphetamine, but did show nonsignificant hyperreactivity to 1 mg/kg amphetamine and a nonsignificantly increased propensity to develop sensitization. A small decrease in D1 receptor binding was seen in the dorsal striatum and olfactory tubercle, and a small decrease of in tyrosine hydroxylase in the olfactory tubercle, but no change was seen in D2 receptor binding. Together, these results support a role for the NK3 receptor in reactivity to dopaminergic stimuli, but the lack of robust changes indicates that the sensitivity to dopamine may be activity-dependent or benign in nature.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18690106 DOI: 10.1097/FBP.0b013e32830cd7f5
Source DB: PubMed Journal: Behav Pharmacol ISSN: 0955-8810 Impact factor: 2.293